Related coverage linked through entity extraction aliases.
Feb 21, 2026
The FDA has accepted Teva and Medincell's New Drug Application for olanzapine extended-release injectable suspension (TEV-'749), a once-monthly subcutaneous treatment for schizophrenia in adults that showed no evidence for post-injection monitoring requirements.
Feb 10, 2026
U.S. Health Secretary Robert F. Kennedy Jr. claimed ketogenic diets can cure schizophrenia, but psychiatry experts say the assertion goes far beyond what current scientific evidence supports.
Feb 21, 2026
The FDA has approved BYSANTI (milsaperidone), a new chemical entity for treating bipolar I disorder and schizophrenia in adults. The drug is Vanda's second approval in less than two months and is expected to launch in Q3 2026.
Feb 21, 2026
Vanda Pharmaceuticals announced FDA approval for BYSANTI tablets to treat Bipolar I manic episodes and schizophrenia in adults. The drug has patent protection extending to 2044 and will be commercially available in Q3 2026.
Feb 17, 2026
Newron Pharmaceuticals has secured up to €38 million in milestone-based financing from European and Asian investors to advance its Phase III ENIGMA-TRS program evaluating evenamide as an add-on therapy for treatment-resistant schizophrenia.
Feb 16, 2026
Researchers identified shared white matter alterations in the corpus callosum as a common biomarker across schizophrenia and bipolar disorder, supporting the concept of a psychosis spectrum rather than distinct disorders.
Dec 30, 2025
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
Aug 15, 2025
Drug Hunter's monthly molecule selections from July through December 2025 feature innovative small molecule candidates targeting pain, epilepsy, cancer, infectious diseases, and metabolic disorders, including non-opioid pain agents and precision therapies for rare conditions.
